CSL Ltd

CSL: XASX (AUS)
View Stock Summary
Morningstar Rating for Stocks Fair Value Economic Moat Capital Allocation
LOCK|!<LOCK|jZvwLOCK|$f>kM<%

CSL: Current Headwinds Appear More Structural and We Temper Our Long-Term Outlook

We have reflected on CSL's soft interim plasma result and temper our view. Immunoglobulin, or lg, sales, which made 57% of plasma sales, fell 6% year on year in constant currency. The former CEO hadn't executed as hoped, with plasma margins up just 10 basis points to 51%.

Sponsor Center